Shalice del Rosario Susana

Ms. Shalice del Rosario Susana

University of the Philippines Diliman, Quezon City, Quezon, Philippines
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 March 2022 in Antioxidants
Verified
Journal Article
Open access
PDF file
Shalice del Rosario SusanaShalice del Rosario Susana
Shalice del Rosario Susana
LSLilibeth Salvador-Reyes
Lilibeth Salvador-Reyes
Chronic inflammation is recognized as a contributor to multiple chronic diseases, such as cancer, cardiovascular, and autoimmune disorders. Here, a natural products-initiated discovery of anti-inflammatory agents from marine sponges was undertaken. From the screening of 231 crude extracts, a total of 30 extracts showed anti-inflammatory activity with no direct cytotoxic effects at 50 μg/mL on RAW 264.7 (ATCC®TIB-71™) murine macrophage cells stimulated with 1 μg/mL lipopolysaccharide (LPS). Bioactivity-guided purification of the anti-inflammatory extract from the sponge Neopetrosia compacta led to the isolation of xestoquinone (1), adociaquinone B (2), adociaquinone A (3), 14-hydroxymethylxestoquinone (4), 15-hydroxymethylxestoquinone (5), and an inseparable 2:1 mixture of 14-methoxyxestoquinone and 15-methoxyxestoquinone (6). Compounds 1–6 caused a concentration-dependent reduction of nitric oxide (NO) production in LPS-stimulated RAW 264.7 cells, with 4–6 having low micromolar IC50 and acceptable selectivity index. Gene expression analysis using qRT-PCR showed that 1, 5, and 6 downregulated Il1b and Nos2 expression by 2.1- to 14.8-fold relative to the solvent control at 10 μM. Xestoquinone (1) and monosubstituted analogues (4–6), but not the disubstituted adociaquinones (2 and 3), caused Nrf2 activation in a luciferase reporter MCF7 stable cells. Compounds 5 and 6 caused a modest increase in Nqo1 gene expression at 10 μM. The anti-inflammatory activity of xestoquinone (1) and monosubstituted analogues (4–6) may, in part, be mediated by Nrf2 activation, leading to attenuation of inflammatory mediators such as IL-1β and NOS2.

28 April 2025 in Phytochemistry Letters
Verified
Journal Article
Closed access
EPErnest Guiller S. Pineda
Ernest Guiller S. Pineda
JPJacquelyn Ervas Peran
Jacquelyn Ervas Peran
JBJeremiah D. Batucan
Jeremiah D. Batucan
ZAZildjian G. Acyatan
Zildjian G. Acyatan
Shalice del Rosario SusanaShalice del Rosario Susana
Shalice del Rosario Susana
LSLilibeth A. Salvador-Reyes
Lilibeth A. Salvador-Reyes

22 September 2024 in SciEnggJ
Verified
Journal Article
Closed access
ZAZildjian Acyatan
Zildjian Acyatan
Shalice del Rosario SusanaShalice del Rosario Susana
Shalice del Rosario Susana
MPMyra Ruth Picart
Myra Ruth Picart
EBEliza Belen
Eliza Belen
LSLilibeth Salvador-Reyes
Lilibeth Salvador-Reyes
GCGisela Concepcion
Gisela Concepcion
Breast cancer continues to be a serious global health concern, necessitating novel treatment approaches. This study explores the potential of combination therapies, investigating the combinatorial effects of doxorubicin (Dox) and renieramycin M (RM) in vivo, previously shown to have synergistic effects in vitro. Single drug administrations and combination treatments were tested on in vivo breast cancer murine models using 4T1-injected BALB/c mice. Tumor volume, animal mortality, and clinical toxicity were monitored, and in silico toxicity assessment was performed. Histopathological analyses using hematoxylin and eosin (H&E) staining, and immunohistochemistry utilizing the p63 breast cancer marker were used for validation. The combination treatment of Dox and RM (5 mg/kg + 1 mg/kg) displayed a 46.53% reduction in tumor volume and an 83.63% decrease in observed metastatic infiltration in the liver. Furthermore, the combination treatment of Dox and RM significantly delayed and reduced the clinical signs of toxicity, as revealed by the decline in observed mortality as opposed to animal deaths in single drug treatments. Our study highlights the potential synergism between Dox and RM as combination therapy for breast cancer treatment. These findings provide possible strategies to improved therapies, offering a more effective and less toxic approach to mitigating breast cancer.